In this article, we will look at the 12 Best 52-Week Low Stocks to Buy According to Analysts.
On July 15, the Consumer Price Index data revealed that core inflation increased by 0.2% on the month; however, the annual rate of 2.9% remains within the estimated range. To discuss this, Torsten Slok, Chief Economist at Apollo Global Management, joined CNBC for an interview. Slok has been one of the economists warning the market that tariffs will be inflationary. He noted that the CPI report marks the start of that inflationary impact. He highlighted that there are various categories in the report that show that the goods part of the report is witnessing growing inflation.
He highlighted that it is very clear that companies built their inventories going into the trade war, and now, with time, those inventories are running out. As a result, as the companies have to buy and import materials at increased prices, the inflation for such goods is going up as well. He says that this is, in his view, exactly what Powell has noted that he expects the inflation to rise meaningfully as a result of tariffs.
With that, let’s take a look at the 12 best 52-Week low stocks to buy according to analysts.
An online investment platform, showing stocks, index funds, and a mutual fund investment platform.
Our Methodology
To curate the list of 12 Best 52-Week Low Stocks to Buy According to Analysts, we used the Finviz stock screener, Yahoo Finance, and CNN. Using the screener, we aggregated a list of stocks trading around 0-5% of their 52-week lows and that analysts expect more than 30% upside for. Next, we cross-checked the 52-week range for each stock from Yahoo Finance and the analyst upside potential from CNN. Lastly, we ranked the stocks in ascending order of their upside potential. We have also added the number of hedge fund holders, sourced from Insider Monkey’s Q1 2025 database. Please note that the data was recorded on July 14, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
12 Best 52-Week Low Stocks to Buy According to Analysts
12. Americold Realty Trust, Inc. (NYSE:COLD)
Price: $16.61
52-Week Range: 16.06 – 30.45
Number of Hedge Fund Holders: 33
Analyst Upside Potential: 32.45%
Americold Realty Trust, Inc. (NYSE:COLD) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 13, Wells Fargo’s analyst Blaine Heck raised the firm’s price target on Americold Realty Trust, Inc. (NYSE:COLD) from $15 to $20, while maintaining a Buy rating on the stock.
The analyst noted that this upgrade was part of the firm’s Q2 preview, where they adjusted price targets within the industrial and cold storage real estate investment trust (REIT) group. The analyst also highlighted that the group’s conservative initial outlooks, combined with Q1 earnings that beat expectations, should help insulate the REITs from negative estimate revisions. However, Heck emphasized the importance of the duration of the current softness in the leasing activity. The duration of this softness in leasing activity is a major factor that will influence investor sentiment and performance going forward.
Americold Realty Trust, Inc. (NYSE:COLD) is a real estate investment trust (REIT) that owns and operates temperature-controlled warehouses globally.
11. Enerpac Tool Group Corp. (NYSE:EPAC)
Price: $37.64
52-Week Range: 36.78 – 51.91
Number of Hedge Fund Holders: 13
Analyst Upside Potential: 35.49%
Enerpac Tool Group Corp. (NYSE:EPAC) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On June 26, Enerpac Tool Group Corp. (NYSE:EPAC) released its fiscal Q3 2025 results.
The company delivered $158.66 million in net sales, reflecting a 5.50% year-over-year growth and ahead of consensus by $2.16 million. The EPS of $0.51 also exceeded expectations by $0.04. Management noted that the company, despite economic uncertainty and a soft industrial sector, delivered positive sales and profit growth. This was attributed to the company’s strong brand, product diversity, and distribution network.
Moreover, Enerpac Tool Group Corp. (NYSE:EPAC) also undertook cost-reduction initiatives and increased prices to offset higher material costs and economic headwinds. Based on the year-to-date performance of the company, management maintained its outlook, expecting net sales between $610 million and $625 million.
Enerpac Tool Group Corp. (NYSE:EPAC) designs, manufactures, and distributes hydraulic and mechanical industrial tools and equipment.
10. Fair Isaac Corporation (NYSE:FICO)
Price: $1,544.23
52-Week Range: 1,484.29 – 2,402.52
Number of Hedge Fund Holders: 68
Analyst Upside Potential: 39.23%
Fair Isaac Corporation (NYSE:FICO) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 9, Jeffrey Silber, analyst at BMO Capital, initiated coverage of Fair Isaac Corporation (NYSE:FICO) with a Buy rating and a price target of $2,000.
Analyst Silber highlighted the company’s strong market position, especially its highly profitable Scores business. The segment benefits from high margins and significant pricing power. Despite recent market worries, Silber expects potential growth driven by an industry volume recovery and continued price increases.
Silber also points to the recent stock decline after comments from the FHFA Director as a good buying opportunity. Historically speaking, such dips have offered favorable entry points for investors. He expresses confidence in the company’s consistent track record, noting that Fair Isaac Corporation (NYSE:FICO) has regularly met or exceeded guidance over the past decade.
Fair Isaac Corporation (NYSE:FICO) develops predictive analytics and decision management software. It helps businesses make better operational decisions by using data science and advanced analytics.
9. Joint Stock Company Kaspi.kz (NASDAQ:KSPI)
Price: $81.47
52-Week Range: 77.80 – 143.72
Number of Hedge Fund Holders: 35
Analyst Upside Potential: 39.95%
Joint Stock Company Kaspi.kz (NASDAQ:KSPI) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On June 17, Morgan Stanley analyst Nida Iqbal lowered the firm’s price target on Joint Stock Company Kaspi.kz (NASDAQ:KSPI) from $127 to $115, while maintaining an Overweight rating on the stock.
The revised price target comes after the firm returned from an investors’ trip to Kazakhstan, Uzbekistan, and Turkey. Morgan Stanley remained positive about Joint Stock Company Kaspi.kz (NASDAQ:KSPI) after the trip; however, they decreased the group’s net income forecast for 2025 by 6%. This was due to the expected losses from the company’s operations in Turkey.
The firm advises investors to be patient because there are near-term challenges ahead. They believe the company will face some headwinds but has good prospects in the medium to long term.
Joint Stock Company Kaspi.kz (NASDAQ:KSPI) is a leading fintech and e-commerce company based in Kazakhstan. It provides an integrated ecosystem of services including online payments, digital banking, and a marketplace for shopping.
8. Globus Medical, Inc. (NYSE:GMED)
Price: $57.12
52-Week Range: 54.48 – 94.93
Number of Hedge Fund Holders: 45
Analyst Upside Potential: 40.06%
Globus Medical, Inc. (NYSE:GMED) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 3, Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Globus Medical, Inc. (NYSE:GMED) with a price target of $80.
The firm maintained a bullish sentiment despite the company posting a weak fiscal first quarter of 2025. Globus Medical, Inc. (NYSE:GMED) posted a revenue of $598.12, slightly down by 1.41% year-over-year, and below consensus by $27.78 million. The EPS of $0.68 also missed the target by -$0.06.
On the bright side, the US sales were steady, rising by 0.2%. Management noted that the main reason for weaker sales was fewer enabling technology deals and some supply chain issues. The timing of orders from international distributors also played a part. Despite these challenges, the company’s US spine business remained strong and offset some of the decline. Management has reaffirmed the full-year guidance and is expecting revenue between $2.8 billion and $2.9 billion.
Globus Medical, Inc. (NYSE:GMED) is a medical device company specializing in developing and commercializing solutions for musculoskeletal disorders.
7. Chemed Corporation (NYSE:CHE)
Price: $459.91
52-Week Range: 457.44 – 623.61
Number of Hedge Fund Holders: 39
Analyst Upside Potential: 41.33%
Chemed Corporation (NYSE:CHE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On June 30, RBC Capital analyst Ben Hendrix lowered the firm’s price target on Chemed Corporation (NYSE:CHE) from $674 to $640, while keeping an Overweight rating on the stock.
Hendrix expressed disappointment due to Medicare cap limitations affecting the company’s 2025 outlook. These limits are expected to weigh on revenue, especially for its hospice care segment, VITAS, in Florida. However, he is encouraged by VITAS receiving a new Certificate of Need (CON) in Pinellas County. This will help VITAS stay strong in a competitive market and manage Medicare cap pressures effectively going forward.
Hendrix also noted headwinds for Chemed Corporation (NYSE:CHE)’s Roto-Rooter segment. He highlights that an unexpected drop in residential volume hurt performance; however, the commercial business improved.
Chemed Corporation (NYSE:CHE) operates two main businesses. Its VITAS segment provides hospice and palliative care services. Whereas, the Roto-Rooter segment delivers plumbing, drain cleaning, water restoration, and related services.
6. Elevance Health, Inc. (NYSE:ELV)
Price: $340.67
52-Week Range: 337.61 – 567.26
Number of Hedge Fund Holders: 75
Analyst Upside Potential: 41.49%
Elevance Health, Inc. (NYSE:ELV) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, UBS analyst AJ Rice lowered the firm’s price target on Elevance Health, Inc. (NYSE:ELV) from $555 to $484, while keeping a Buy rating on the stock.
The cautious rating comes as the company gets close to releasing its Q2 2025 earnings. The analyst noted that Elevance Health, Inc. (NYSE:ELV) is the only managed care organization with government exposure showing meaningful positive EPS growth. However, he lowered the price target on the caution that the company might revise its earnings in the upcoming conference call.
During the fiscal first quarter of 2025, the company delivered revenue of $48.8 billion, up 15.4% year-over-year. Its adjusted operating gains also grew 4.1% to reach $3.3 billion. Management reaffirmed FY 2025 adjusted diluted EPS of $34.15 to $34.85 during the Q1 2025 earnings call.
Elevance Health, Inc. (NYSE:ELV) is a leading health insurer in the United States, providing a wide range of health plans and pharmacy services.
5. Freshpet, Inc. (NASDAQ:FRPT)
Price: $68.39
52-Week Range: 66.75 – 164.07
Number of Hedge Fund Holders: 36
Analyst Upside Potential: 53.53%
Freshpet, Inc. (NASDAQ:FRPT) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 9, Wells Fargo analyst Marc Torrente lowered the firm’s price target on Freshpet, Inc. (NASDAQ:FRPT) from $100 to $88, while keeping an Overweight rating on the shares.
The price adjustment comes as the firm is aggregating its model across beverages, food, and HPC industries and updating price targets. Freshpet, Inc. (NASDAQ:FRPT) is also set to release its Q2 2025 earnings call on August 4. During the fiscal first quarter of 2025, the company grew its net sales by 17.6% to $263.2 million. Management expects net sales for the full year to be between $1.12 billion $1.15 billion.
Freshpet, Inc. (NASDAQ:FRPT) develops, manufactures, markets, and distributes fresh, refrigerated pet food products.
4. PG&E Corporation (NYSE:PCG)
Price: $13.42
52-Week Range: 13.34 – 21.72
Number of Hedge Fund Holders: 76
Analyst Upside Potential: 56.48%
PG&E Corporation (NYSE:PCG) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 7, PG&E Corporation (NYSE:PCG) announced that it is calling for innovators to help solve California’s toughest energy challenges. The company has up to $25 million to fund new projects. They want entrepreneurs, inventors, and tech experts to join their 2025 Innovation Pitch Fest.
The event will take place from September 23 to September 25, at PG&E’s Oakland headquarters. It focuses on breakthrough technologies that need strong collaboration between PG&E and external innovators. The company updated its strategy in 2024, highlighting key problem areas and increased emphasis on using Artificial Intelligence to improve energy systems.
For this year’s Innovation Pitch Fest, PG&E Corporation (NYSE:PCG) has set 10 specific problem statements. They include challenges like managing the energy demands of growing AI data centers, accelerating neighborhood electrification, reducing wildfire risks, and improving safety through AI. PG&E wants fast, scalable solutions to these urgent problems.
PG&E Corporation (NYSE:PCG) is a major utility serving northern and central California. It provides electricity and natural gas to about 16 million people across a 70,000-square-mile area.
3. Braze, Inc. (NASDAQ:BRZE)
Price: $26.47
52-Week Range: 25.22 – 48.33
Number of Hedge Fund Holders: 31
Analyst Upside Potential: 62.45%
Braze, Inc. (NASDAQ:BRZE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On June 24, Oppenheimer lowered the firm’s price target on Braze, Inc. (NASDAQ:BRZE) from $44 to $38, while keeping an Outperform rating on the stock.
The analyst highlighted that the main reason for this reduction is “lower group multiples” in the sector, not a reflection of the company’s business performance. During a meeting with the company’s management, Oppenheimer found that the company is optimistic as management sees good momentum in enterprise segments, international markets, and verticals like financial services and healthcare. They do not expect significant macroeconomic or industry risks that could affect guidance despite a smaller renewal cohort in Q2.
Oppenheimer views Braze, Inc.’s (NASDAQ:BRZE) valuation as fair given its mid-to-high teens revenue growth and potential for margin expansion. They believe the current multiple limits further downside risk to the stock.
Braze, Inc. (NASDAQ:BRZE) is a technology company that provides a customer engagement platform that helps brands connect with their customers in real time across multiple channels.
2. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Price: $29.51
52-Week Range: 29.03 – 60.37
Number of Hedge Fund Holders: 55
Analyst Upside Potential: 174.48%
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), while lowering the price target from $80 to $79.
The firm held its positive outlook even after the recent challenge from the FDA’s complete response letter for UX111 in Sanfilippo syndrome. The CRL was focused on specific chemistry, manufacturing, and controls issues. Importantly, the clinical data for UX111 was not questioned; however, the approval is still achievable once the CMC issues are resolved.
The analyst noted that the company is responding quickly and plans to address the CMC concerns and resubmit its Biologics License Application in the coming months. The analyst is also optimistic due to Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) robust pipeline. The company has promising programs for conditions like osteogenesis imperfecta and Angelman syndrome.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops treatments for rare and ultra-rare genetic diseases. They focus on biologics, small molecules, gene therapy, and nucleic acid products.
1. Biohaven Ltd. (NYSE:BHVN)
Price: $13.93
52-Week Range: 13.74 – 55.70
Number of Hedge Fund Holders: 37
Analyst Upside Potential: 309.19%
Biohaven Ltd. (NYSE:BHVN) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On June 10, Biohaven Ltd. (NYSE:BHVN) announced that it has started a research collaboration with Bexorg, Inc. targeting central nervous system (CNS) disorders.
Bexorg, which is a techbio company, has a platform that can revive and study whole human and pig brains using artificial blood. This technology helps them see how drugs affect actual brain tissue. The platform produces deep data about how genes and proteins behave in disease and health.
Both companies will use this technology to help design and test new therapies for CNS conditions. As a result of this collaboration, two Biohaven Ltd. (NYSE:BHVN) preclinical programs will benefit from these unique brain studies. Bexorg’s approach offers a big leap ahead of normal lab models.
Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company that develops and commercializes treatments for diseases in immunology, neuroscience, and oncology.
While we acknowledge the potential of BHVN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BHVN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
